Issues related to rare disease treatments, including rare disease research incentives; Issues related to H.R. 1262/S. 932 - Give Kids a Chance Act; Issues related to Medicaid changes in the One Big Beautiful Bill Act (PL 119-21); Issues related to drug pricing reforms.
2025 · 3rd Quarter (July 1 - Sep 30)
ACADIA PHARMACEUTICALS, INC.
Filed by TIBER CREEK GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 19, 2025
- Income
- $80,000.00
- Expenses
- Not reported
- Registrant
- TIBER CREEK GROUP
- Filing UUID
- 2e7ac4a0-da42-4874-bd8c-1df6dc64d1a8
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to the orphan drug tax credit.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.